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ABSTRACT
Hospital- and community-acquired Staphylococcus aureus infections pose a substantial burden in terms of
morbidity, mortality and healthcare costs. The introduction of new antibiotics to counter this pathogen
has frequently been closely followed by the emergence of resistant strains. Most significantly, S. aureus
isolates resistant to b-lactams have become common, and many of these are also resistant to b-lactamase-
resistant penicillins. The rapid spread of methicillin-resistant S. aureus (MRSA) clones across the world
often results in hospital outbreaks, but implementation of appropriate control measures usually reduces
prevalence to sporadic levels. However, the recent emergence of MRSA infections in the community,
affecting patients with no established risk factors for MRSA acquisition, is likely to impact significantly
on future strategies for control of nosocomial MRSA. In contrast to other antibiotic classes, S. aureus
resistance to glycopeptides did not emerge until nearly 40 years after their clinical introduction, and as a
result this drug class has remained the mainstay of treatment for MRSA infections. However, a number
of vancomycin-intermediate S. aureus isolates have emerged worldwide and four fully resistant S. aureus
isolates have been reported in the USA. This raises the concern that the current first-line treatment for
MRSA infection may become ineffective in an increasing proportion of cases in the near future. New
classes of antibiotic are urgently needed to treat infections with this growing population of multidrug-
resistant S. aureus, and the recently introduced oxazolidinone linezolid and the cyclic lipopeptide
daptomycin are welcome additions to the ever-narrowing range of therapies effective against this
pathogen.
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INTRODUCTION: THE CURRENT
SITUATION
Staphylococcus aureus is a major cause of hospital-
and community-acquired infections, and can
result in serious consequences [1]. Hospital infec-
tions caused by S. aureus include those affecting
the bloodstream, lower respiratory tract, skin and
soft tissues, as well as ventilator-assisted pneu-
monia and central venous catheter-associated
bacteraemia. These infections can lead to substan-
tial morbidity and mortality, as well as high
healthcare costs. This situation has been exacer-
bated by the rising incidence of strains that are
less susceptible to a variety of antibiotics, making
treatment of these infections more difficult.
The SENTRY Surveillance Program investi-
gated the worldwide extent of infections caused
by S. aureus between January 1997 and December
1999 [1]. Bloodstream isolates from 15 439
patients infected with S. aureus and 6350 patients
infected with coagulase-negative Staphylococcus
species were referred by SENTRY-participating
hospitals in the USA, Canada, Latin America,
Europe and the Western Pacific region. S. aureus
was the most common overall cause of bacterial
infections involving the bloodstream, lower res-
piratory tract and skin ⁄ soft tissue (Table 1) [1].
Indeed, 32–47% of all skin ⁄ soft tissue infections
appeared to be caused by S. aureus [1].
The importance of S. aureus as a human patho-
gen, apart from its ability to cause a diverse range
of life-threatening infections, is its extraordinary
potential to develop antimicrobial resistance [2].
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This review will focus on the development of
antimicrobial resistance in S. aureus, including the
evolution of resistant strains, their spread into the
community and molecular mechanisms of resist-
ance, with a particular emphasis on methicillin
and vancomycin resistance.
EMERGENCE OF ANTIMICROBIAL
RESISTANCE
Causes of antibiotic resistance
History has shown that the introduction of a
new antibiotic is frequently followed by the
development of bacterial antibiotic resistance, as
antibiotic use provides the potential for selection
of resistant strains [3]. There are several under-
lying reasons for this phenomenon: (1) antimi-
crobial use is the key driver of resistance and,
paradoxically, this selective pressure comes
from a combination of overuse in many parts
of the world (e.g., for minor infections or in
food-producing animals), misuse due to lack of
access to appropriate treatment, and failure to
complete treatment courses [3]; (2) inherent
microbial characteristics also play a role—for
example, S. aureus resistance to penicillin is
highly prevalent, and yet Streptococcus pyogenes
strains are uniformly susceptible to penicillin,
which remains the drug of choice for treating
infections caused by this organism [4]; and (3)
societal and technological traits also contribute
to the spread of antibiotic resistance due to
substantial increases in the availability and ease
of travel within and between countries [2].
MACROLIDE, LINCOSAMIDE AND
STREPTOGRAMIN RESISTANCE
Macrolides, lincosamides and streptogramins,
which were first introduced in 1952, constitute
a group of antibiotics collectively known as
MLS. They target the bacterial 50S ribosomal
subunit, thereby effectively inhibiting protein
synthesis [5]. As some patients were allergic to
penicillin, MLS antibiotics provided welcome
alternatives for treating staphylococcal infec-
tions. However, resistance to the new antibiotics
emerged shortly afterwards in strains of S. aur-
eus, as resistance genes were already present,
and use of these antibiotics exerted a selective
pressure [5,6]. T
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In S. aureus, MLS resistance has two pheno-
types. The first is due to ribosomal modification
by 23S rRNA methylases, mediated primarily by
ermA, ermB or ermC (found on plasmids or
chromosomes), preventing antimicrobial agents
from binding to their ribosomal target site [5,6].
The second resistance type is mediated by msrA
and involves the active efflux of the
antimicrobial agent by an ATP-dependent
pump, thereby maintaining intracellular concen-
trations below the level required for binding to
ribosomes [6].
Aminoglycoside resistance
Aminoglycosides were introduced in 1944, and by
the 1950s aminoglycoside-resistant strains of
S. aureus had emerged [7]. These drugs enter
bacterial cells by energy-dependent binding to the
cell wall and energy-dependent transport across
the cytoplasmic membrane, finally binding to one
or more ribosomal sites, thus inhibiting protein
synthesis [5]. Resistance in staphylococci results
from any of three events: (1) a chromosomal
mutation leading to altered aminoglycoside bind-
ing to ribosomes; (2) ineffective transport of
aminoglycosides into the bacterial cell, producing
low-level cross-resistance to most aminoglyco-
sides; and, most commonly, (3) enzymic modifi-
cation of aminoglycosides [2]. In the last case,
resistant strains have the aminoglycoside-modi-
fying genes acc, aph and ant, which code for
aminoglycoside acetyltransferases, phospho-
transferases and adenyltransferases, respectively
[5,8]. The acetylated, phosphorylated or adenyl-
ated aminoglycosides do not bind to ribosomes,
and thus do not inhibit protein synthesis [8].
Quinolone resistance
Although fluoroquinolones were introduced in
the 1980s for the treatment of Gram-negative
bacterial infections, their Gram-positive spectrum
of activity meant that they were also used to treat
infections caused by pneumococci and staphylo-
cocci [2]. The primary target of quinolones is
bacterial DNA gyrase, without which DNA rep-
lication is inhibited [5]. Quinolone resistance
emerged rapidly, particularly among methicillin-
resistant strains, by the stepwise acquisition of
chromosomal mutations. This involved mutations
in the quinolone-resistance-determining region of
the enzyme–DNA complex, reducing the affinity
of quinolone for its targets (DNA gyrase and
topoisomerase IV) [2].
b-LACTAM RESISTANCE
The penicillins isolated from fermentation broths
of Penicillium chrysogenum were found to be very
active against Gram-positive and Gram-negative
cocci [7]. When penicillin G was initially intro-
duced in the early 1940s, over 85% of S. aureus
isolates were susceptible to < 0.1 mg ⁄L, but
penicillin-resistant staphylococci appeared within
3 years. By 1948, up to 50% of hospital strains
were resistant, with the level of resistance rising
to 80% by 1957 [7]. Resistance is due to the
production of a penicillinase (or b-lactamase).
More than 90% of staphylococcal isolates now
produce b-lactamase, which inactivates b-lactam
antibiotics by hydrolysis of their b-lactam ring [2].
BlazA encodes b-lactamase and is part of a
transposable element on a plasmid, which often
also contains genes resistant to other antibiotics,
(e.g., gentamicin and erythromycin) [2].
Methicillin, the first of the semi-synthetic pen-
icillinase-resistant penicillins, was introduced in
1961 to target strains of penicillinase-producing
S. aureus [2,8]. However, resistance to methicillin
was reported very quickly after its introduction
[9]. Resistance occurs following the chromosomal
acquisition of novel DNA, resulting in the pro-
duction of a new penicillin-binding protein,
termed PBP2a, with a low binding affinity for
methicillin [8]. PBP2a substitutes for all other
penicillin-binding proteins, and because of its low
affinity for all b-lactam antibiotics it confers
resistance to all b-lactam agents, including
cephalosporins [2]. PBP2a is encoded by mecA,
part of the mobile genetic element, the staphylo-
coccal chromosomal cassette mec (SCCmec) [8].
The source of mecA is unknown; however, it has
been suggested that it was acquired from a
coagulase-negative staphylococcal species such
as Staphylococcus sciuri [2,10].
Waves of clonal dissemination of methicillin-
resistant S. aureus (MRSA) strains spread rapidly
across the world, accounting for varying propor-
tions of nosocomial S. aureus infections in differ-
ent countries [2]. Of particular interest is
the prevalence of methicillin resistance among
S. aureus isolates in various European countries
(Fig. 1) [11]. Data were collected from January
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1999 to December 2002, and involved 50 759
isolates from 495 hospitals in 26 countries. MRSA
prevalence varied almost 100-fold, from <1% in
northern Europe (Sweden, Denmark and The
Netherlands) to > 40% in Greece, the UK and
Italy. This study also showed considerable varia-
tion in MRSA proportions among hospitals within
a country. This regional variation may be
explained by different phenomena. The emer-
gence of MRSA is largely due to dissemination of
clonal strains, and temporary hospital outbreaks
are typically due to clonal expansion [11]. How-
ever, if effective control measures are taken to
prevent further MRSA transmission, MRSA pre-
valence may be reduced to sporadic levels [11,12].
The effectiveness of MRSA control depends on
several factors, including good hygiene (e.g.,
hand hygiene, isolation practices and cohort
nursing of patients with MRSA), level of care
needed by patients (e.g., indicating host suscep-
tibility), and antimicrobial drug prescription poli-
cies (which would influence selective pressure)
[11,12]. Rapid application of these hygiene and
control measures at the hospital level, as well as at
the regional level, may be successful in containing
the MRSA epidemic [12].
The prognosis for patients infected with MRSA
is generally worse than that for patients infected
with methicillin-susceptible S. aureus (MSSA).
This was demonstrated by a meta-analysis of
S. aureus bacteraemia that showed a significant
increase in mortality associated with MRSA
(OR 1.93, 95% CI 1.54–2.42; p < 0.001) [13]. Rather
than any enhanced virulence of the MRSA strains,
this difference is thought to be associated with
patient age and disease severity, as well as the
relative lack of effective antibiotic treatments for
MRSA [2]. A study investigating cases of S. aureus
bacteraemia during a hospital outbreak of MRSA
over a 4-year period showed that patients with
MRSA bacteraemia were older than those with
MSSA bacteraemia (69 years vs. 54 years, respect-
ively; p < 0.01) [14]. Patients with MRSA bacter-
aemia were also more likely than those with
MSSA to have the following predisposing factors:
prolonged hospitalisation (32 vs. 14 days, respect-
ively; p < 0.01); prior antimicrobial therapy (61
vs. 34%, respectively; p < 0.01); urinary catheter-
isation (58 vs. 27%, respectively; p < 0.01); naso-
gastric tube placement (31 vs. 13%, respectively;
p < 0.01); and prior surgery (45 vs. 31%, respec-
tively; p 0.05) [14]. It is also interesting to note
that mortality rates in patients with MRSA or
MSSA in nosocomial pneumonia are high, even if
they are correctly treated for these strains (50 vs.
34%, respectively; p 0.34) [15].
Although MRSA was until recently considered
a healthcare-associated pathogen, several recent
reports have documented the emergence of infec-
tions in non-healthcare settings, in patients with
no established risk factors for MRSA acquisi-
tion. Methicillin resistance in these community-
acquired MRSA isolates has most commonly been
associated with SCCmec type IV [16]. In contrast
to nosocomial MRSA infection, infections caused
by community-acquired MRSA are often mild
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Fig. 1. The prevalence of methicillin
resistance among Staphylococcus
aureus blood isolates in Europe [11].
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and similar to those caused by MSSA, but severe
infections, including necrotising fasciitis and nec-
rotising pneumonia, have been reported [17,18].
Reported prevalence rates vary, but a recent meta-
analysis found a pooled MRSA colonisation rate
of 0.2% among community members without
healthcare contacts [19]. It is likely that this
reservoir of community-acquired MRSA will con-
tinue to expand, potentially leading to endemicity
within the community—a situation that could
well have a substantial negative impact on the
control of nosocomial MRSA [20].
Glycopeptide resistance
Following the spread of MRSA, glycopeptides
(usually vancomycin and more recently teicopla-
nin) have become the mainstay of treatment for
MRSA infections. Vancomycin was introduced in
1958, but the first fully vancomycin-resistant
S. aureus (VRSA) clinical isolates were found in
2002 [21]. Prior to this, vancomycin-intermediate
S. aureus (VISA) strains were isolated, first in
Japan in 1996, and then in many other countries,
including the USA, prompting widespread con-
cern. As nearly 40 years transpired between the
introduction of vancomycin and the emergence of
the first case of VISA, and as resistance was
difficult to induce in vitro, many thought that
vancomycin resistance was unlikely to occur in a
clinical setting. However, subsequent events have
disproved this hypothesis. Four clinical VRSA
isolates have now been reported, all in the USA
(two from Michigan, and one each from Pennsyl-
vania and New York), each from a single patient.
In addition to worries that strains of S. aureus
have emerged with total resistance to vancomy-
cin, these VRSA isolates also have a different and
potentially much more efficient mechanism for
dissemination than VISA strains. Whereas resist-
ance in VISA strains is thought to occur solely as a
result of alterations in peptidoglycan synthesis,
VRSA strains are thought to acquire additional
resistance by conjugal transfer of plasmids con-
taining the vanA operon from vancomycin-resist-
ant Enterococcus faecalis. Resistance in VRSA
strains is caused by alteration of the cell wall
terminal peptide D-alanyl-D-alanine to D-alanyl-
D-lactate, preventing the inhibition of cell-wall
synthesis by vancomycin. VISA strains appear to
be selected from a population heterogeneous for
vancomycin resistance (in the presence of
vancomycin, which exerts a selective pressure).
These VISA strains synthesise greater quantities
of peptidoglycan with more exposed D-alanyl-D-
alanine residues to bind and trap vancomycin,
which may then act, in addition to the thickened
cell wall found in these strains, to prevent drug
molecules reaching the target of the cytoplasmic
membrane. The specific resistance genes for VISA
and VRSA strains are, as yet, unknown.
It is difficult to assess the effect of heterogene-
ous VISA, VISA and VRSA on clinical outcomes,
as these are relatively recent phenomena, and
thus there are few published studies. However,
one study has examined treatment outcomes in
patients (n ¼ 25) with serious infections caused
by MRSA with reduced vancomycin susceptibility
(MICs of 2–4 mg ⁄L) [22]. In this study, eight
patients had endocarditis, nine had bacteraemia
associated with a deep-seated infection, six had
osteomyelitis or septic arthritis, and two had
empyema. All patients had previously received
vancomycin for a median period of 15 days; this
treatment failed for 19 of 25 patients (76%).
Although second-line treatment was usually
effective (in 24 of 25 cases; 96%), surgical inter-
ventions were required in 60% of patients
(n ¼ 15). Thus, second-line antibiotic therapy,
especially linezolid with or without rifampicin
and fusidic acid, in conjunction with surgical
debulking, was effective for the majority of
patients with serious infections, including endo-
carditis, caused by MRSA with reduced vanco-
mycin susceptibility [22].
CONCLUSIONS
The history of the development and introduction
of antibiotics, together with the often rapid
emergence of resistance in S. aureus, shows that
this organism has a remarkable capacity for
adapting to new types of antimicrobial agents.
As a consequence, there is a growing population
of S. aureus that is resistant to traditional antibi-
otics and their derivatives. Moreover, this resist-
ance is moving from the hospital to the
community, thus posing an even greater threat
than before. New classes of antibiotic are needed
to overcome this threat. In 2000–2001, the oxazo-
lidinone linezolid became the first new antimi-
crobial drug specifically targeting Gram-positive
bacteria to enter clinical use since the glycopep-
tides in the 1950s. More recently, the cyclic
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lipopeptide daptomycin was introduced into clin-
ical practice in the USA in 2003 and is expected to
be available in Europe early in 2006. It is hoped
that these new agents will help to combat the
threat posed by the spread of S. aureus strains
resistant to the older antimicrobial agents.
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